News
AMGN
287.21
+0.32%
0.91
Should You Invest in the iShares Biotechnology ETF (IBB)?
NASDAQ · 12h ago
Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates
NASDAQ · 1d ago
Notable Tuesday Option Activity: CAL, CEIX, AMGN
NASDAQ · 2d ago
Dow Movers: BA, AMGN
NASDAQ · 2d ago
Wall Street Awaits Consumer Confidence Data
NASDAQ · 2d ago
Viking Therapeutics gains on early data for oral weight loss therapy
Seeking Alpha · 2d ago
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
NASDAQ · 2d ago
Wall Street Set to Post Fifth Winning Month Amid Volatility
NASDAQ · 2d ago
Validea Detailed Fundamental Analysis - AMGN
NASDAQ · 3d ago
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Amgen (AMGN) and Petiq (PETQ)
TipRanks · 3d ago
Weekly Report: what happened at AMGN last week (0318-0322)?
Weekly Report · 3d ago
Sanofi: My Top Pick In Big Pharma
Seeking Alpha · 3d ago
PureTech Health: Repeat What Works
PureTech Health's lead asset, LYT-100, may be a promising treatment for idiopathic pulmonary fibrosis. Karuna Therapeutics was acquired by BMY for $14 billion in December. The company has been successful in developing a therapeutic with an optimized profile.
Seeking Alpha · 5d ago
ITOT, DIS, AMGN, RTX: Large Outflows Detected at ETF
NASDAQ · 6d ago
ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study
NASDAQ · 03/21 15:12
Is Amgen Stock a Buy Now?
Biotech giant Amgen's shares are down by 5% since Jan. 1. The company's total revenue increased by 7% year over year. Amgen is one of the world's largest and most prominent drugmakers. The key is to develop newer drugs, and Amgen has a promising pipeline. The drugmaker is an excellent defensive stock.
The Motley Fool · 03/21 11:00
Tracking John Paulson's Paulson & Company Portfolio - Q4 2023 Update
John Paulson's 13F portfolio value decreased slightly from $1.12B to  $1.11B in the last quarter. The top five positions in the portfolio are Madrigal Pharma, Bausch Health, NovaGold, and Perpetua Resources. Paulson is best known for his bets against the real-estate bubble.
Seeking Alpha · 03/19 23:52
Amgen (AMGN) Ascends But Remains Behind Market: Some Facts to Note
NASDAQ · 03/19 21:50
3 Potential Biotech Buyout Targets In 2024
Biotech sector saw a surge of M&A activity at the end of 2023. The small biotech sector surged by 50% off its late October lows. 2024 should be a solid year for acquisitions in the biotech/biopharma space. Big drug makers have large cash balances and face key patent expirations. Three potential buyout targets in 2024 are highlighted below.
Seeking Alpha · 03/19 14:16
Bristol-Myers Squibb Is Not A Buy For Me
Bristol-Myers Squibb's revenue is at risk from loss of patent exclusivity over the next several years. The company has turned to acquisitions to fortify its pipeline and revenue streams. BMY's acquisition of Celgene in 2019 was one of the largest pharmaceutical mergers in history. Key Revlimid and Eliquis products face the challenge of declining sales.
Seeking Alpha · 03/19 10:46
More
Webull provides a variety of real-time AMGN stock news. You can receive the latest news about Amgen Inc through multiple platforms. This information may help you make smarter investment decisions.
About AMGN
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness. It also offers TEPEZZA (teprotumumab-trbw), KRYSTEXXA (pegloticase) and UPLIZNA (inebilizumab-cdon).